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Background
Pregnancy is a physiological prothrombotic state. Venous 
thromboembolism (VTE) is a leading cause of direct 
maternal death well described in the MBRRACE reports.1 
In addition, many adverse pregnancy outcomes, including 
fetal growth restriction (FGR), pregnancy loss, pre-
eclampsia and placental abruption, which collectively 
affect up to 15% of pregnancies,2 share similar and over-
lapping micro- and macro thrombotic pathogenic pro-
cesses. The high physical and psychological burden of 
such adverse pregnancy outcomes makes the develop-
ment of targeted and effective preventative interventions a 
significant issue for obstetric care. Despite limited evi-
dence of benefit, the well-known association between 
thrombophilias and adverse pregnancy outcomes has led 
to widespread use of prophylactic low-molecular-weight 
heparin (LMWH) in pregnancy, as there are few interven-
tions with biological plausibility for an effect.
Physiological prothrombotic changes 
in pregnancy
Hypercoagulability is a physiological adaptation in preg-
nancy, reflecting a number of alterations in coagulation 
and fibrinolytic pathways, which are summarised in Table 
1. This hypercoagulant state increases through pregnancy, 
peaking at term.2,3
The endogenous anticoagulants, activated protein C 
(APC) and its vitamin K–dependent cofactor protein S, are 
reduced in pregnancy.4–6 Fibrinolysis is reduced in preg-
nancy largely due to placenta-derived PAI-2; however, this 
normalises rapidly post-delivery.7
As pregnancy advances, tissue factor–dependent 
thrombin generation increases, along with Factors VII, 
VIII, IX, fibrinogen, prothrombin fragment 1+2 and 
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thrombin-antithrombin complexes.8,9 D-dimer levels 
increase through pregnancy reflecting the overall changes 
in coagulation and fibrinolysis in pregnancy.9
The placenta itself has procoagulant characteristics, 
with high levels of tissue factor expressed in trophoblast 
cells.10 However, there are also inhibitory mechanisms 
such as endothelial protein C receptor, thrombomodulin, 
annexin V and tissue factor pathway inhibitor, which 
increases from the 10th week of pregnancy.7,11
Inherited thrombophilias
The most common inherited thrombophilias are Factor V 
Leiden (FVL) and Factor II (prothrombin) G20210A, 
which affect 3–11% of the population; less prevalent 
(<1%) inherited thrombophilias include protein C, protein 
S and antithrombin deficiency, dysfibrinogenemias and 
hyperhomocysteinemia.12–14
FVL
FVL accounts for 40–50% of inherited thrombophilias, 
with a prevalence of heterozygosity of 3–8% in the 
United States and Europe and as high as 8.8% in the 
white British population.15 It is an autosomal dominant 
condition with incomplete penetrance, characterised by 
a relative resistance to active Protein C, leading to the 
inability of Protein C to cleave Factors Va and VIIIa 
because of a mutation at the cleavage site as a conse-
quence of a single-nucleotide polymorphism. Its clinical 
expression varies depending on its homo- or heterozygo-
sity and coexisting genetic and acquired disorders and 
risk factors.15
Factor II (prothrombin) G20210A 
heterozygotes
The prothrombin G20210A polymorphism is a prevalent 
genetic variant in white populations with incidence 
of 1–6%. Factor II G20210A increases prothrombin and 
thus greater thrombin generation and concurrently 
reduces APC-mediated inactivation of Factor Va.16 This 
in turn leads to a prothrombotic state.
Protein C deficiency
Protein C is a vitamin K–dependent natural anticoagulant, 
which inactivates Factors Va and VIIIa, thereby inhibiting 
thrombin generation.17 Its deficiency can be a result of 
multiple different genetic mutations, leading to varying 
degrees of hypercoagulability.18
Protein S deficiency
Protein S is a vitamin K–dependent cofactor of protein 
C, which only cleaves Factors Va and VIIIa in its free 
form.19 Since Protein C anticoagulant activity is depend-
ent on Protein S, deficiency in Protein S is associated 
with hypercoagulability. Protein S also has Protein 
C–independent roles, in which it directly inhibits factor 
Xase and prothrombinase and interacts with tissue factor 
pathway inhibitor to further inhibit factor Xa.20 Its pro-
tein C–independent mechanisms are enhanced by 
LMWH.20
Antithrombin deficiency
Antithrombin deficiency can be acquired and inherited; 
the inherited condition has a prevalence of 1 in 500–5000.21 
Antithrombin inactivates thrombin and Factor Xa; there-
fore, its deficiency promotes coagulation.21 Quantitative 
Type I antithrombin deficiency results from heterozygous 
point mutations or major gene deletions leading to reduc-
tion in levels and function of antithrombin.22 The more 
common qualitative Type II is associated with normal 
antithrombin levels and reduced function and is further 
categorised into IIa, b or c depending on which part of 
antithrombin is affected by the mutation.21 Antithrombin 
functional assay is the initial investigation of choice, in 
order not to miss Type II deficiency. If abnormal, 
antithrombin antigen levels will distinguish between the 
two types. Functional assays assessing inhibitory activity 
on Xa have a higher sensitivity than those assessing throm-
bin and some patients with Type II antithrombin deficiency 
have only slightly reduced or even normal function, thus 
increasing the complexity of its diagnosis.21
Dysfibrinogenemias
Congenital dysfibrinogenemias are rare and have an auto-
somal dominant pattern of inheritance.23 They result in 
defects in the thrombin–fibrinogen reaction, preventing 
the conversion of soluble fibrinogen into insoluble fibrin. 
This in turn can lead to thrombosis, bleeding and defec-
tive wound healing.23
Table 1. Haemostatic changes in pregnancy.
Anticoagulation/fibrinolysis Procoagulation
Protein S ↓ Prothrombin (Factor II) ↑
Activated protein C ↓ in 
third trimester
Factor V ↑
Plasminogen activator 
inhibitor-1 ↓
Factor VII ↑
Factor VIII ↑
Factor IX ↑
Factor X ↑
Fibrinogen ↑
D-dimer ↑
Systemic platelet activation 
↑ in late pregnancy
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Hyperhomocysteinemia
Different inherited enzyme defects can lead to hyperhomo-
cysteinemia. The most common is a single-nucleotide poly-
morphism in the methylene tetrahydrofoalte reductase 
gene, MTHFR 677T. Homocysteine, when auto-oxidated, 
can lead to the production of biologically reactive products 
and increased cell toxicity. The four consequential disease 
processes include thrombosis, oxidant stress, apoptosis and 
cellular proliferation.24 Folic acid, B12 and B6 supplements 
reduce circulating homocysteine levels; however, the clini-
cal significance of this has yet to be demonstrated.25
Thrombophilia and pregnancy
Data largely from retrospective cohorts and case control 
studies have shown that inherited thrombophilias are asso-
ciated not only with VTE but also with adverse pregnancy 
outcomes including recurrent miscarriage and gestational 
vascular complications.26 Initial reports such as that of 
Kupferminc et al.27 reported as many as 65% of women 
with pre-eclampsia, unexpected stillbirth, placental abrup-
tion and FGR had some form of thrombophilia. More 
recent data, including from prospective studies, have dem-
onstrated a more modest association. The evidence is sum-
marised in Table 2. Inherited thrombophilias have also 
been linked to fertility problems and implantation failure, 
although no causal relationship has been proven.29 As the 
overall effect of inherited thrombophilias on adverse preg-
nancy is modest, this suggests that their effect is likely to 
be contributory rather than a primary cause.
Biological plausibility for thrombophilia and 
pregnancy complications
A satisfactory placental circulation is required for success-
ful pregnancy development. Inadequate placental perfu-
sion may reflect micro thrombotic events, which lead to a 
reduction in trophoblast invasion and chronic hypoxia.2 
This is thought to prompt gestational vascular complica-
tions including FGR, late pregnancy loss, placental 
abruption and pre-eclampsia, which affect up to one in six 
pregnancies.30 It is therefore logical to consider that pro-
thrombotic conditions, including the inherited thrombo-
philias discussed in this review, could lead to an increased 
risk in such pregnancy complications. There are a number 
of examples, which demonstrate this biological plausibil-
ity in animal models.
The pathogenesis underlying the epidemiological and 
theoretical association between thrombophilias and 
adverse pregnancy outcomes has been studied. For exam-
ple, Isermann et al.31 studied mice with a disrupted gene 
coding for thrombomodulin. At the feto-maternal inter-
face, thrombomodulin deficiency was associated with 
embryo abortion.31 This study demonstrated the essential 
role of thrombomodulin in trophoblast growth and sur-
vival. At the feto-maternal interface, thrombomodulin 
deficiency stimulates a procoagulant cascade, thereby 
precipitating giant trophoblast cell death and arrest of 
growth of trophoblast cells.31
A report of mice with FVL highlighted the synergistic 
effect of both maternal and fetal thrombophilic mutations.32 
They found that FVL mice with fetal gene defects experi-
enced fetal loss. This study also demonstrated that fetal loss 
was secondary to Par4-mediated platelet activation, interest-
ingly in the absence of overt thrombosis. This has demon-
strated the high-risk pregnancy model of concurrent fetal and 
maternal thrombophilia as well as a haemostatic pathogene-
sis independent of thrombosis.
The study by Jianzhong et al.33 further complicated the 
role of thrombophilia and LMWH in recurrent pregnancy 
loss. The protective effect of LMWH on murine pregnan-
cies was not reciprocated by fondaparinux, despite its 
comparable anticoagulant effect. This has highlighted a 
potential anticoagulant-independent effect of LMWH on 
placental development and the heterogeneity of placental-
mediated complications.
Early pregnancy loss
Heritable thrombophilias are associated with early 
pregnancy loss. A systematic review reported that 
Table 2. Summary of associations between heritable thrombophilia and adverse pregnancy outcome.
VTE Early 
pregnancy 
loss
Recurrent 
first-trimester 
loss
Second-
trimester 
loss
Late 
pregnancy 
loss
Pre-
eclampsia
Placental 
abruption
FGR
Factor V Leiden ↑ ↑ ↑/←→ ↑ ↑ ↑ ↑ ←→
Prothrombin G20210A ↑ ↑ ↑/←→ ↑ ↑ ↑ ↑ ←→
Protein C deficiency ↑ ←→ ←→ ←→ ↑ ←→ ←→
Protein S deficiency ↑ ←→ ←→ ↑ ←→ ←→ ←→
Antithrombin deficiency ↑ ←→ ←→ ←→ ←→ ←→
Hyperhomocysteinemia ←→ ←→ ←→ ←→ ↑ ←→ ←→
Data taken from Robertson et al.26 and Rey et al.28
VTE: venous thromboembolism; FGR: fetal growth restriction.
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homozygotes for FVL and heterozygotes for FVL and 
prothrombin G20210A are at increased risk of early 
pregnancy loss (odds ratio (OR) 2.71 (95% confidence 
interval (CI) 1.32–5.58), 1.49 (95% CI 1.09–2.58) and 
2.49 (95% CI 1.24–5.00)), respectively.26 The other 
inherited thrombophilias showed no association with 
early pregnancy loss.
Recurrent first-trimester loss
There are modest associations between recurrent first-
trimester loss and prothrombin G20210A heterozygo-
sity, and with FVL (OR 2.70 (95% CI 1.37–1.69) and 
1.91 (95% CI 1.01–3.61), respectively).26 Such a weak 
association would again be consistent with thrombo-
philia being a contributory factor rather than a single 
cause of such complications.
Second- and third-trimester pregnancy loss
FVL and prothrombin G20210A heterozygotes have a 
stronger association with second-trimester loss than other 
early pregnancy loss (OR 4.12 (95% CI 1.93–8.81) and 
8.60 (95% CI (0.44–1.69), respectively.26 This was con-
sistent with an earlier systematic review, which reported 
the strongest association to be between FVL and preg-
nancy loss after 19 weeks.28 Rodger et al.’s34 updated 
meta-analysis in 2014 looked at pregnancy loss irrespec-
tive of gestation and similarly found patients with FVL to 
be at increased risk (risk ratio 1.79 (95% CI 1.06–3.03)); 
it did not, however, find associations between prothrom-
bin G20210A heterozygotes and overall pregnancy loss. 
Fewer studies exist for Protein C and S deficiency and 
poor pregnancy outcomes; however, Robertson’s system-
atic review demonstrated a significant association 
between Protein S deficiency and late pregnancy loss 
although confidence intervals were wide reflecting small 
numbers (OR 20.1 (95% CI 3.70–109.15)).26 There was 
no association with Protein C deficiency.
Pre-eclampsia
There is a modest association between FVL heterozygo-
sity, prothrombin 20210A and MTHRR C677T homozy-
gotes.26 However, this was not confirmed in the systematic 
review of prospective studies.35
Placental abruption
Only two inherited thrombophilias have demonstrated 
statistically significant associations with risk of placen-
tal abruption; these are FVL heterozygotes and pro-
thrombin G20210A heterozygotes.26 Again, however, 
no association was found on meta-analysis of prospec-
tive studies.35
FGR
Although a generalised association between thrombophilia 
and FGR was demonstrated in a meta-analysis of five stud-
ies, meta-analyses of individual inherited thrombophilias 
demonstrated no significant association.32,35
VTE
VTE is a leading cause of direct maternal death1 and 
thrombophilia is an established risk factor. For this rea-
son, appropriate risk stratification and prophylaxis is cru-
cial in women with thrombophilia in pregnancy. A 
systematic review demonstrated a relative increase in 
VTE risk in all inherited thrombophilias except homozy-
gotes for MTHFR C677T; one explanatory hypothesis is 
that routinely taken folic acid supplements reduce homo-
cysteine levels, thus reducing an increased VTE risk.26 In 
contrast, the highest relative risk of VTE was associated 
with homozygous FVL (34.4%), translating to an absolute 
risk of 3.4%.26 The more common thrombophilias demon-
strated a weaker association. Early reports on the risk of 
VTE associated with deficiencies of antithrombin, Protein 
C and Protein S may have overestimated the risk due to 
methodologic limitations such as selection bias in family 
studies36,37 as more recent estimates suggest a much lower 
level of risk.38 A significant risk factor is family history of 
VTE, irrespective of thrombophilia; this increases risk 
twofold to fourfold.39
Current guidance
The lack of a strong and consistent evidence base to under-
pin clinical guidelines leads to differing recommendations 
in clinical guidelines such as from the American College 
of Chest Physicians (ACCP)38 compared with the Royal 
College of Obstetricians and Gynaecologists (RCOG) 
guideline on thromboprophylaxis40 (Tables 3 and 4).
Given the weaker association between the more com-
mon thrombophilias and VTE and the significant risk factor 
of positive family history, the ACCP guidance recommends 
LMWH prophylaxis in two groups of women: (1) with no 
family history of VTE who are either homozygotes of FVL 
or prothrombin gene mutations; or (2) women with family 
history of VTE in combination with any other inherited 
thrombophilia.38 The ACCP guideline does not recommend 
prophylactic LMWH use for those with inherited thrombo-
philias in the absence of previous pregnancy complications. 
This is justified by the lack of the existing evidence for 
improvement in pregnancy outcome by LMWH in women 
with inherited thrombophilias and recurrent pregnancy 
loss.38 However, the ACCP guideline does recommend 
aspirin for those who are at high risk of pre-eclampsia, irre-
spective of thrombophilia history. This is in-keeping with 
the American Congress of Obstetricians and Gynecologists 
(ACOG)41 and supported by a strong evidence base.42
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The RCOG guidelines similarly recommend ‘consider-
ation’ of antenatal LMWH prophylaxis in asymptomatic 
patients with homozygosity for FVL and prothrombin 
G20210A.40 This guideline also recommends considera-
tion of LMWH prophylaxis in women with antithrombin, 
Protein C or Protein S deficiency, despite the absence of 
family/personal history of VTE,40 which differs from the 
ACCP guidance.38 The RCOG guideline further stratifies 
risk by pragmatic accumulation of risk factors: if heterozy-
gosity for FVL or prothrombin gene mutation is present 
with two or three other risk factors, or there is compound 
heterozygosity, prophylactic LMWH can be given antena-
tally. Another difference between the two guidelines is that 
the RCOG guideline40 applies risk stratification to dosing 
differences, suggesting that women with antithrombin 
deficiency and previous VTE should have 50–100% treat-
ment dose antenatally and for 6 weeks postnatally.
ACCP and RCOG are just two examples of internationally 
available guidelines. The variation between these two guide-
lines alone exemplifies the lack of an adequate evidence base.
Table 3. Recommendations for thromboprophylaxis for women with inherited thrombophilia in pregnancy.
History of VTE Inherited thrombophilia Antenatal management Postnatal management
Previous VTE Antithrombin deficiency 50–100% treatment dose LMWH
Involve haematologist
Anti-Xa monitoring
50–100% treatment dose 
LMWH × 6 weeks/until oral (PO) 
anticoagulation started
All others Consider prophylactic dose LMWH Prophylactic dose LMWH × 6 weeks
Asymptomatic Antithrombin deficiency
Protein C deficiency
Protein S deficiency
Compound heterozygotes
Homozygous FVL If more than one thrombophilic defect, 
consider prophylactic dose LMWH
If more than one thrombophilic 
defect, for prophylactic dose 
LMWH × 6 weeks
Homozygous prothrombin gene 
mutation
Heterozygous FVL Consider prophylactic dose LMWH in 
the presence of three other risk factors/
from 28 weeks if two other risk factors
Prophylactic dose LMWH × 10 days 
if one other risk factorHeterozygous prothrombin gene 
mutation
Data taken from RCOG Green-top guideline no. 37a.40
VTE: venous thromboembolism; LMWH: low-molecular-weight heparin; FVL: Factor V Leiden.
Table 4. ACCP guidelines for thromboprophylaxis for women with inherited thrombophilia in pregnancy.
History of VTE/pregnancy 
complication
Inherited thrombophilia Antenatal management Postnatal management
Previous VTE Any inherited thrombophilia Prophylactic or intermediate 
dose LMWH
Prophylactic or intermediate 
dose LMWH × 6 weeks
Asymptomatic but has 
family history of VTE
Homozygous for Factor V 
Leiden
Prophylactic or intermediate 
dose LMWH
Prophylactic or intermediate 
dose LMWH or vitamin K 
antagonists (INR 2-3) × 6 weeks
Homozygous for prothrombin 
gene mutation
Prophylactic or intermediate 
dose LMWH
Prophylactic or intermediate 
dose LMWH or vitamin K 
antagonists (INR 2-3) × 6 weeks
Protein C or S deficiency Thromboprophylaxis not 
recommended
Prophylactic or intermediate 
dose LMWH × 6 weeks
All other inherited 
thrombophilias
Thromboprophylaxis not 
recommended
Prophylactic or intermediate 
dose LMWH or vitamin K 
antagonists (INR 2-3) × 6 weeks
Asymptomatic and no 
family history of VTE
Any inherited thrombophilia Thromboprophylaxis not 
recommended
Thromboprophylaxis not 
recommended
Previous pregnancy 
complications
Any inherited thrombophilia Thromboprophylaxis not 
recommended
Thromboprophylaxis not 
recommended
High risk of pre-eclampsia Irrespective of thrombophilia 
history
Low-dose aspirin from 
second trimester
Thromboprophylaxis not 
recommended
Data taken from Bates et al.38
ACCP: American College of Chest Physicians; VTE: venous thromboembolism; LMWH: low-molecular-weight heparin; INR: international  
normalised ratio.
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Discussion
There is an evidence base for management of VTE, in part, 
extrapolated from the non-pregnant population; however, 
the evidence base is limited for adverse pregnancy out-
comes as discussed above. Due to the safety and relatively 
low side-effect profile of low-dose aspirin (LDA) and 
LMWH, as shown in Table 5,43,44 the biological plausibility 
for an effect, extrapolation from Antiphospholipid syn-
drome (APS)45 and the lack of alternative interventions, 
they have been introduced into care of groups at high risk 
of adverse pregnancy outcome in advance of evidence. 
Indeed, in three major randomised trials in women selected 
on the basis of previous pregnancy complications alone 
(rather than thrombophilia), such treatment was ineffec-
tive.46–48 Interestingly, however, the trials from Gris 
et al.49,50 on prevention of adverse pregnancy outcomes in 
women with a history of pre-eclampsia and abruption 
treated with LMWH showed significant benefit from 
LMWH. Of note, the women studied had a higher preva-
lence of thrombophilia (ca. 15%). In these randomised con-
trolled trials, the pre-eclampsia rate was 5.8% with LMWH 
compared with 16.7% in the controls, and the incidence of 
severe pre-eclampsia was also significantly reduced in the 
LMWH cohort with a rate of 0.9% compared with 7.1%.49 
In women with a past history of abruption, the composite 
outcome of at least one of pre-eclampsia, placental abrup-
tion, birth weight under the fifth centile and fetal loss after 
20 weeks was significantly lower in the LMWH group 
(12.5% compared with 31.3%).50
Furthermore, meta-analysis of six trials in this area is 
also consistent with some evidence of benefit from LMWH. 
In this meta-analysis, the study population was not specific 
to thrombophilia, but included pregnant women who had 
previous pregnancy complications including pre-eclampsia, 
placental abruption, small for gestational age (SGA) (<10th 
centile), second- and third-trimester pregnancy loss,51 there 
was a significant reduction in the recurrence rate (18.7% 
in the LMWH group, versus 42.9% in the controls, relative 
risk reduction, 0.52; 95% CI 0.32–0.86). They had similarly 
positive secondary outcomes with pre-eclampsia, SGA 
and preterm delivery. This demonstrates the potential for 
LMWH to be of value for women with previous placenta-
mediated pregnancy complications, but requires corrobora-
tion with high-quality multicentre studies.
For women with a thrombophilia and history of adverse 
pregnancy outcome, this is an emotive area. Clinicians 
have no proven effective treatment, yet there is demand 
from patients for an intervention that might help. Clinicians 
are therefore obliged to actively manage such risk factors, 
despite the lack of good quality evidence supporting this. 
Although an increase in relative risk of VTE and adverse 
pregnancy outcomes has been demonstrated in the litera-
ture for those with inherited thrombophilias, the absolute 
risk is often low and the interventions are costly and do not 
come without risk. It is therefore important to consider the 
limited evidence behind these interventions.
For women with heritable thrombophilia, small non- 
randomised trials and observational studies have suggested 
some benefit.8 However, this contrasts with data from 
recently reported randomised trials. The TIPPS trial studied 
women with thrombophilia and previous placenta-mediated 
pregnancy complications or VTE in a randomised trial of 
146 women assigned to antepartum LMWH versus 143 
assigned to no antepartum LMWH. There was a higher pro-
portion of LDA use in the control group (40% versus 30%).52 
Given the fact that LDA has not previously been shown to be 
of benefit in such women, the difference in LDA use in the 
two groups should not affect the reliability of the data.45 The 
trial demonstrated no significant reduction in adverse preg-
nancy outcome with LMWH treatment.52 With regard to 
safety, major bleeding did not differ between the two groups, 
but minor bleeding was more common in the LMWH group 
(risk difference 10.4%, 95% CI 2.3–18.4; p = 0.01).
The FRUIT trial studied LMWH intervention in 139 
women with inherited thrombophilia and a history of pre-
vious early-onset gestational hypertensive disorder.53 In 
contrast to the TIPPS trial, it only recruited patients at less 
Table 5. The safety of LMWH in pregnancy.
Complication Greer and Nelson-Piercy43
Systematic review
Rate %
(n = 2777)
Nelson-Piercy et al.44
Retrospective study
Rate %
(n = 1267)
VTE (overall) 0.86 1.19
VTE recurrence on treatment 1.15 1.97
Bleeding Significant bleeding: 1.98 
(1.50–2.57)
PPH > 500 = <1000 mL: 11
PPH > 1000 = <1500 mL: 0.9
PPH > 1500 mL:1.1
Wound haematoma 0.61 0.9
Heparin-induced thrombocytopenia 0.00 0
Osteoporosis 0.04 0.2
LMWH: low-molecular-weight heparin; VTE: venous thromboembolism; PPH: postpartum haemorrhage.
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than 12 weeks gestation and all patients received LDA. A 
significant reduction in hypertensive disease recurrence 
before 34 weeks gestation was demonstrated in women 
treated with LMWH and LDA compared with LDA alone, 
with a risk reduction of 8.7% (CI 1.9–15.5%; p = 0.012).53 
However, the overall hypertensive disease recurrence rate 
was unchanged with no difference in maternal or fetal 
outcome with no significant difference in gestation at 
delivery, only a reduction in antenatal steroid use in the 
LMWH group consequent upon the reduction in recur-
rence before 34 weeks of gestation.
Given the biological plausibility for a thrombotic mech-
anism and the potential for LMWH to impact on this, it is 
important to consider whether LMWH might still have a 
role in this disease process following the reports of the 
TIPPS and the FRUIT trials. There are data that show 
potential benefit from LMWH treatment on implantation 
and placental development including some data that sug-
gest benefit on pregnancy outcome from LMWH in 
assisted conception treatment.28 This leads to the hypoth-
esis that the pathogenic processes originate in the first tri-
mester. If this is the case, it is important to consider the 
timing of treatment in relation to implantation. In the 
TIPPS trial, less than 30% were recruited before 8 weeks’ 
gestation.52 This highlights the need to examine LMWH 
administration in the peri-implantation period.
Furthermore, similarities between the different placenta-
mediated complications, including deficient implantation 
and placental infarction, have led to the theory that they 
share the same haemostatic pathological processes8 and 
would therefore benefit from the same intervention. Perhaps 
this is naive as different disease mechanisms may be operat-
ing. Due to the complex multifactorial aetiologies of such 
outcomes and the heterogeneity of women studied in previ-
ous trials, it is possible that more convincing evidence for 
successful intervention may unfold if further research is tar-
geted better through a disease process-specific approach.8 
This highlights the need for further research into the under-
lying disease mechanisms to allow better patient stratifica-
tion, with a precision medicine approach allowing clinical 
trials to target more homogeneous populations with a dis-
ease process amenable to an antithrombotic intervention.
Such trials are not easy as evidenced by the TIPPS 
trial, which took 12 years to complete with centres in sev-
eral countries.51 Therefore, to recruit sufficient numbers 
of women with well-characterised disease mechanisms 
for a precision medicine trial will likely require a multi-
centre international collaboration. Such an approach with 
a more homogeneous patient group is underway with the 
ALIFE 2 trial, which is randomising pregnant women 
of less than 7 weeks’ gestation and confirmed inherited 
thrombophilia with a history of two or more miscarriages 
or intra-uterine fetal deaths, or both to LMWH plus stand-
ard pregnancy surveillance versus standard pregnancy 
surveillance alone (www.ALIFE2study.org).
Conclusion
The widespread use of prophylactic anticoagulant and anti-
platelet therapy for women with thrombophilia and a history 
of adverse pregnancy outcome based on the logical associa-
tion between thrombotic processes and these complications 
has overridden the paucity of data supporting this treatment. 
Despite some studies demonstrating potential benefit of 
LMWH in women with previous placenta-mediated compli-
cations, there is as yet no good quality evidence supporting 
its antenatal use in those with inherited thrombophilia.
This lack of evidence may reflect the multifactorial 
nature of these complications, heterogeneity of the study 
groups with inadequate stratification or the variation in 
gestation at which LMWH has been introduced in these 
studies. Acquiring such evidence is not easy. The TIPPS 
trial clearly demonstrates the difficult and lengthy pro-
cess. In the meantime, clinicians and patients will need 
guidance on the management of these conditions based on 
the current evidence including the need to continue to pur-
sue clinical trials in this area. Only with research to pro-
vide a better understanding of the disease processes, 
identification of possible biomarkers and better-targeted 
treatment can we guide clinical decision making in this 
important and emotive area.
Future perspective
In 5 years, precision medicine, which is already widely 
used in cancer care, will hopefully have been introduced 
into obstetrics. With progressing research into the patho-
physiology of adverse pregnancy outcomes and potential 
biomarkers, we should have sufficient knowledge for cat-
egorisation and risk stratification of adverse pregnancy 
outcomes by their disease process rather than their clinical 
outcome. Randomised trials of interventions targeted on 
specific disease processes will accumulate to create a 
sounder evidence base to better inform management in this 
complex area.
Executive summary
•• Pregnancy is a physiological prothrombotic state.
•• VTE is a leading cause of direct maternal death.
•• Adverse pregnancy outcomes, including FGR, 
pregnancy loss, pre-eclampsia and placental 
abruption, share similar micro- or macro throm-
botic pathogenic processes.
•• Heritable thrombophilia is associated with both 
gestational VTE and adverse pregnancy outcomes.
•• The association between heritable thrombophilia 
and poor pregnancy outcomes has led to widespread 
use of prophylactic LMWH based on the safety of 
LMWH, biological plausibility for benefit and lack 
of alternative interventions.
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•• Trials of intervention with LMWH for adverse 
pregnancy outcomes show inconsistent results with 
no overall evidence of a major benefit, including 
women with both heritable thrombophilia and a his-
tory of previous adverse pregnancy outcome.
•• The inconsistent evidence base may reflect the mul-
tifactorial nature of these complications and hetero-
geneity of the study groups with inadequate 
stratification, or the variation in gestation at which 
LMWH has been introduced in these studies.
•• Research is required to provide a better understand-
ing of the disease processes, identify possible bio-
markers to guide treatment and examine the 
possible benefits of better-targeted antithrombotic 
treatment.
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